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Abstract
Background: In Canada, the legalization of cannabis has enabled cannabidiol (CBD) to become a popular
commercial product, increasingly used for medical or therapeutic purposes. There are currently over one thousand
CBD products available globally, ranging from oil extracts to CBD-infused beverages. Despite increased usage and
availability, the evidence supporting the medical efficacy of CBD is limited. Anecdotal evidence suggests CBD sellers
represent their products for medical use through direct medical claims or advice, which in Canada, is not allowed
under the Cannabis Act without Health Canada approval. However, it is not clear the extent of sellers making health
claims or other strategies used to promote medical usage of CBD. The objective of this study is to determine how
CBD sellers advertise their products online to consumers.
Methods: The product descriptions of 2165 CBD products from 70 websites selling CBD products for human
consumption in Canada were collected from January 14th, 2020 to February 2nd, 2020 using an automated website
scraper tool. A framing analysis was used to determine how CBD sellers frame their products to prospective
customers. The specific medical conditions CBD is represented to treat and product forms were tabulated.
Results: CBD products are framed to prospective customer through three distinct frames: a specific cure or
treatment (n = 1153), a natural health product (n = 872), and a product used in certain ways to achieve particular
results (n = 1388). Product descriptions contained medical or therapeutic claims for 171 medical conditions and
ailments, with 53.3% of products containing at least one claim. The most prevalent claims found in product
descriptions were the ability to treat or manage pain (n = 824), anxiety (n = 609), and inflammation (n = 545). Claims
were found for treating or managing serious and-life-threatening illnesses such as multiple sclerosis (n = 210),
arthritis (n = 179), cancer (n = 169), Crohn’s disease (n = 78), Parkinson’s disease (n = 59), and human
immunodeficiency virus (HIV) (n = 54). CBD most often came in oil/tincture/concentrate form (n = 755), followed by
edibles (n = 428), and vaporizer pen/cartridge/liquid products (n = 290).
Conclusion: The findings suggest CBD is represented as a medical option for numerous conditions and ailments.
We recommend Health Canada to conduct a systematic audit of companies selling CBD for regulatory adherence.
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Background
The popularity of cannabidiol (CBD) – one of many can-
nabinoids found in cannabis and hemp plants – has in-
creased in Canada and globally in recent years [1]. By
2024, the CBD industry expects to reach a market valu-
ation of 20 billion USD [2]. CBD products are diverse -
they include cosmetic products such as makeup, hygiene
products such as shampoos, edibles, beverages, oils, and
vaporizer products such as infused vape pens or liquids.
Media sources often attribute CBD’s popularity to its
representation as a medicinal cannabis product, capable
of treating numerous conditions and ailments without
the psychoactive effects of tetrahydrocannabinol (THC)
[3–5]. The majority of medical cannabis users in Canada
(41%) reported using products with higher CBD content
over products with high THC [6]. CBD retailers and
proponents commonly advertise CBD as helpful for uses
such as inflammation, pain, epilepsy, depression, insom-
nia, anxiety, cancer, multiple sclerosis, skin health, and
Alzheimer’s disease [3, 7–10]. Academics and journalists
alike have pointed out that CBD is described as a ‘cure-
all’ despite limited research confirming such general or
specific claims [10–13].
At present, only one CBD-derived medication for rare
seizure disorders – Epidiolex – is clinically accepted for
treatment by the Food and Drug Administration (FDA)
in the United States [14]. In Canada, there are three
products containing cannabis approved for sale with
drug identification numbers – Sativex, Marinol, and the
synthetic cannabinoid Nabilone [15]. Marinol was volun-
tarily withdrawn from market. The supporting evidence
for CBD medical uses besides seizure relief is promising
but in the early stages of development [16–18].
Cannabis sellers, including sellers of CBD, are not
allowed to make health or therapeutic claims in Canada
or the United States. Under the Cannabis Act, the legis-
lation governing cannabis products in Canada: “It is pro-
hibited to promote cannabis, a cannabis accessory or a
service related to cannabis … if there are reasonable
grounds to believe that the promotion could create the
impression that health or cosmetic benefits may be de-
rived” [19]. The Cannabis Act also stipulates that canna-
bis cannot be promoted in a “manner that is false,
misleading or deceptive or that is likely to create an er-
roneous impression about its characteristics, value,
quantity, composition, strength, concentration, potency,
purity, quality, merit, safety, health effects or health
risks” [20]. Similarly, the United States prohibits the
marketing of CBD products with unproven medical
claims [21].
Despite the existence of regulations, there is evidence
to suggest that sellers of CBD are representing their
products as medical options for serious illnesses. In No-
vember of 2019, the FDA issued warnings to 15
companies making unproven claims of CBD efficacy for
conditions such as cancer and Parkinson’s disease [22].
Similar observations are reported in Canada. For ex-
ample, an unlicensed CBD brand known as ‘Mona Lisa
Healing’ made claims during the COVID-19 pandemic
that their CBD can “help your body defend against
COVID-19 coronavirus” [23]. Marijuana Business Daily,
a cannabis industry news source, acknowledges the med-
ical representation of CBD products to prospective con-
sumers: “Cannabis products with unauthorized health
claims are commonly sold in unregulated channels, es-
pecially products containing CBD” [24]. It is unclear if
such claims are widespread across the CBD industry or
an outlier, and thus represent an area of needed
research.
The present study contributes to filling this research
gap by systematically exploring how CBD products are
advertised for sale on Canadian cannabis retail websites.
Approximately 20% of medical cannabis users in Canada
order their products online [6]. Sellers of CBD typically
seek to describe the benefit(s) of purchasing their prod-
uct, and thus online product messaging is an ideal
source to determine how retailers are representing CBD
products to consumers. The exploration of online CBD
product advertisements in Canada will contextualize in-
dustry adherence to existing Government of Canada reg-
ulations and inform public health policies.
Methods
To identify CBD products available for sale online by
Canadian retailers, two Google searches of ‘buy CBD
Canada’ and ‘buy cannabidiol Canada’ were completed
on January 14th, 2020. The website URL on the first 20
pages of each search (400 URLs retrieved) was recorded.
This broad search term phrasing mimics Google
searches a prospective CBD consumer may use to iden-
tify and find information on CBD products. After identi-
fying 400 websites that potentially sell CBD products, a
duplicate filter left 296 websites for review to determine
if they sold CBD to Canadian consumers.
For inclusion into the study, the websites retrieved
must have sold at least one CBD product for human
consumption/use and it must have been possible to pur-
chase such products from the website directly, without a
medical provider’s approval or license. The website oper-
ators must also have been based in Canada or individu-
ally operated a Canadian division and thus were subject
to Canadian regulations. After implementing a review of
each website, 68 websites met the inclusion criteria.
During the review, seven websites selling CBD were
identified as being run by a provincial or territorial gov-
ernment, inclusive of British Columbia, Alberta, Ontario,
New Brunswick, Newfoundland and Labrador, Yukon,
and Nova Scotia. We searched for other government-
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run online retailers in the other provinces or territories
not identified in the original website search. After doing
so, an additional two websites were added, from Prince
Edward Island and the Northwest Territories, totaling 70
identified websites selling CBD in Canada. The
remaining provinces and territories (Saskatchewan,
Manitoba, and Nunavut) did not have a government-run
CBD retail website.
The first author then retrieved each CBD product
URL from the 70 included websites. We considered
CBD products to be those that through naming or prod-
uct description contained an equivalent or higher
amount of CBD than THC. The URLs from each website
were searched and collected through one of three ways:
(1) reviewing all products included in CBD-specific sec-
tions of websites; (2) reviewing products identified from
a ‘CBD’ and ‘cannabidiol’ keyword search in the search
function of the website; or (3) in the absence of a search
function or CBD section, hand searching all pages of a
website to identify and review products. After the web-
site reviews were completed, a total of 2165 CBD prod-
uct URLs were recorded by website.
To collect product details, including product name, com-
pany, CBD form, product description, and price, two
methods were used. The website and its associated URLs
were either data scraped using custom made DataMiner
codes (n = 34 websites) or the information manually re-
trieved through visiting the website and recording the
above data fields (n = 36 websites). Decisions to use either
method depended on (1) the number of URLs/product de-
scriptions to extract by website, where generally, more than
15 products led to the development of a scraper code, or
(2) if website contained protections where a scrape job
could not be completed due to reasons such as a manual
requirement to confirm the user was not a computer bot,
age verification checks, or other formatting issues.
After collection, each author independently reviewed
10% of products and met to determine an appropriate
analytic framework. After discussion, we agreed to use
case study methodology where framing analysis - a
qualitative analysis technique to examine how informa-
tion (e.g., an advertisement, a new story) is framed to
convey a particular belief – to explore how online CBD
product retailers in Canada framed CBD product uses
and benefits in their web advertisements [25, 26]. After
further independent data review and another collabora-
tive meeting we confirmed three dominant frames for
CBD products, which was that they were: (1) a treatment
or cure for specific ailments; (2) a natural health prod-
uct; and (3) a product used in specific ways to achieve
particular results. To support our exploration of the first
and third frames, we also counted the specific medical
conditions or medical applications suggested in the CBD
product descriptions on the reviewed websites.
Results
The websites identified (n = 70) had on average 30.9
(median, 21) CBD products for sale (see Table 1). The
most popular form of CBD product available was oil/
tincture/concentrate (n = 755), followed by edibles (n =
428), vaporizer pen/cartridge/liquid (n = 290), topical/
cosmetic products (n = 200), capsules/pills/soft gels (n =
178), dried cannabis flower products (n = 163), bath
products (n = 80), beverages (n = 36), patches (n = 21),
assorted product (n = 7), suppositories (n = 5), and other
forms (n = 2) (see Table 2).
Frame #1: treatment or cure for specific ailments
The first framing theme identified, treatment or cure for
specific ailments (n = 1153 products), contained product
claims of suggestive efficacy and effectiveness for 171
medical conditions, ailments or symptoms (Table 3 sum-
marizes claims with a minimum frequency of 20 claims).
Treatment and curative claims ranged from minor ail-
ments such as pain, inflammation, or bruising, to severe
ailments such as replacement of conventional cancer
treatment, Parkinson’s disease treatment, and neuro-
logical conditions. For example, a dried flower product
from the bestpotdelivery.ca website stated their product
was “very effective for chronic medical conditions like
bipolar disorder, chronic stress, depression, panic at-
tacks, anxiety disorders, and post-traumatic stress dis-
order” and that “one lungful and you’ll feel all your
depression and stress melt away.” Other CBD product
descriptions contained long lists of purported treatments
and conditions. For example, a product description for a
CBD infused lollipop from herbapproach.com listed the
following purported uses: “Medical Conditions [treated
by CBD]: ADD, ADHD, Anxiety, Appetite, Arthritis,
Asthma, Back Pain, Bipolar Disorder, Body Pain, Cach-
exia, Cancer, Cramps, Crohn’s Disease, Depression, Epi-
lepsy, Fibromyalgia, Gastrointestinal Disorder,
Glaucoma, Headaches, Hepatitis C, HIV/Aids, IBS, In-
flammation, Insomnia.”
To support CBD as a treatment for the numerous con-
ditions or ailments collected in the product descriptions,
retailers or the CBD companies provided references to
published research studies or used anecdotal feedback
from their customers or, in some cases, themselves.
When describing the research, retailers often used
animal-based studies or study designs that were not suit-
able for clinical adoption to support their claims. For ex-
ample, a CBD capsule product from thehealingco.ca
stated: “A rarely discussed health benefit of CBD oil is
how it can reduce the risk of developing diabetes. In a
study … 32% of the mice that received the CBD were di-
agnosed with diabetes, compared to 100% of the un-
treated group.” The details of the studies, including
information on study limitations, were often not
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Table 1 Number of CBD Products by Website and Framing Code
Website Framing #1: Treatment or
Cure
Framing #2: Natural Health
Product




herbapproach.com 72 46 85 118
cbd-oil-canada.ca 66 55 84 111
leaf2go.ca 31 21 85 109
thehealingco.ca 59 34 63 96
birchandfog.com 66 37 65 85
budlab.ca 76 51 60 81
justcannabis.shop 56 25 64 80
chilliwackcbd.ca 57 44 60 78
cbd2go.ca 52 55 55 75
shopcbdonline.ca 39 28 52 74
magnoliawellness.ca 53 34 23 73
buybudnow.ca 25 41 46 71
speedgreens.ca 14 10 24 53
mjnexpress.ca 27 22 28 46
cannabis-nb.com 0 7 12 44
bccannabisstores.com 0 6 22 43
albertacannabis.org 0 6 10 42
weedsmart.ca 2 1 11 40
topshelfexpress.ca 12 11 25 40
buymyweedonline.ca 37 12 37 38
motacannabisproducts.ca 35 5 27 37
mailorder-marijuana.ca 27 8 30 36
canadablissherbals.com 24 18 25 34
happybears.ca 26 28 29 32
ocs.ca 0 7 15 29
sqdc.ca 8 19 9 29
shopcannabisnl.com 0 0 0 28
buycbdcanada.ca 19 15 17 27
delta9.ca 0 1 8 27
buymellow.com 12 22 14 24
feelcbd.ca 18 21 23 24
getkush.ca 12 15 13 24
greensociety.ca 17 10 19 23
cannabiscare.ca 11 11 17 22
cannabis.shoppersdrugmart.ca 22 0 22 22
headz.ca 8 7 14 20
lowcloud.ca 10 7 8 20
ganjaexpress.ca 12 1 10 19
westcoastsupply.ca 12 6 11 18
canadaonlinethc.ca 3 1 3 18
balancecbd.com 1 15 17 17
thefoggyforest.ca 13 2 3 16
platinumherbalcare.com 14 6 9 16
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disclosed. For example, a CBD infused vaporizer liquid
from thefoggyforest.ca stated: “A lot of studies have been
done that point to CBD being beneficial for fighting can-
cer. Less potent cancer cells were found in breast tu-
mours when a person uses CBD.” The product
description further states: “[T]here’s also one study that
shows dependent cell death thanks to the CBD oil. This
non-toxic compound, when used at 700 mg per day for
six weeks, showed no signs of toxicity.”
Testimonials for product efficacy were referenced in
some product descriptions. Statements of anecdotal ef-
fectiveness did not make general claims, but rather de-
tailed how they had been helpful for certain people and
relieved their symptoms or condition. For example, a
product description from a CBD Move gummy product
on the healingco.ca website contained anecdotal feed-
back from the company founder and his social network.
Table 1 Number of CBD Products by Website and Framing Code (Continued)
Website Framing #1: Treatment or
Cure
Framing #2: Natural Health
Product




high420.ca 2 7 8 15
tokyosmoke.com 0 2 6 15
canadacannabisdispensary.ca 5 7 8 13
peicannabiscorp.com 0 5 2 12
cannabisdispensary.ca 11 3 7 12
greencanadacbd.ca 9 8 9 11
budsandbeyond.ca 6 1 5 9
firstwonder.ca 9 2 9 9
cannabisyukon.org 1 2 0 9
cannacanine.ca 8 1 1 8
bestpotdelivery.ca 7 6 8 8
vitalityhealthcbd.com 3 6 8 8
greenleafexpress.ca 2 8 8 8
earthchoicesupply.com 8 8 8 8
calyxwellness.co 6 5 6 6
honestbotanicals.ca 4 5 6 6
zenabis.com 0 0 5 6
houseofcannabis.ca 2 0 6 6
cannawholesalers.ca 4 2 4 6
canadianbotanicaldrops.ecwid.com 6 6 6 6
icaria.co 1 5 5 6
bcweedpen.com 4 0 0 4
cbddirectonline.ca 1 4 3 4
cbdme.store 1 4 1 4
hemp-canada.ca 3 2 3 3
okanagancbd.com 2 2 2 2
doseofcanna.ca 0 0 0 2
Total 1153 872
Table 2 Number of CBD Products by Form
Form Frequency
Oil / Tincture / Concentrate Products 755
Edibles 428
Vape pen / cartridge / liquid / kit 290
Topical / cosmetic 200
Capsules / pills / softgels 178
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He described how his experience with CBD had moti-
vated him to bring the benefits to others: “After an in-
jury, the creator of CBD Move discovered the power of
CBD. As he says himself [he] started recommending
CBD to friends and relatives suffering from different
physical ailments, arthritis, headaches etc. Every single
time CBD provided them ease and welcome relief.” The
framing of CBD as a treatment or cure for specific ail-
ments was represented through direct claims, seller in-
terpretation of CBD research, and through anecdotal
product testimonials.
Frame #2: natural health product
The second framing identified, a natural health product
(n = 872 products), sold the natural benefits of CBD and
its advantage over conventional health products. Most
often, products described CBD as a natural option to
treat pain. For example, a CBDfx lotion product sold on
the chilliwackcbd.ca website stated: “This skin-
nourishing cream lets you target your pain ‘hot spots’
with the healing power of 150 mg of full-spectrum CBD
hemp oil and other natural pain relievers.” Products in
Table 3 Number of Medical Claims by Condition/Symptom
































Attention deficit disorder (ADD) 54
Headache 54
Human immunodeficiency virus (HIV) 54
Acne 52







Energy (fatigue relief) 44
Neuroprotective 43
Table 3 Number of Medical Claims by Condition/Symptom
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numerous cases advocated using CBD in place of other
conventional medications or treatments. These ranged
from minor substitutions, such as using CBD for inflam-
mation, to suggestions of potential treatment replace-
ment of severe illnesses. For example: “Over the past few
decades, informed consumers have begun a major shift
away from synthetic pharmaceutical drugs with their
long lists of debilitating side effects, in favour of health-
enhancing natural remedies” and that “CBD, from hemp
is providing that all-natural solution for many, and word
of its success at providing an amazing variety of thera-
peutic benefits for a host of physical and mental
disorders.”
Natural framing of CBD commonly described the cul-
tivation methods and additional ingredients or precau-
tions used to formulate the product. Natural health
product terms such as “organic”, “pure”, “non-GMO”,
“pesticide-free”, and “naturally grown” were viewed in
product descriptions as selling qualities. For instance, an
edible CBD infused gummy product from balancecbd.
com made the following statement to support the role of
organically produced products on health: “Our tasty
gummies are made with the finest organic ingredients,
without any animal by-products, cementing our commit-
ment to providing a natural way to enjoy the benefits of
CBD.” Another tincture product from
earthchoicessupply.com used a similar method of selling
the organic production of their product and its effect on
health: “try our 3000mg Premium Hemp Tincture Oil if
you want a quick and effective way of getting all the
benefits offered by this unique plant. Natural and Or-
ganic are the best words to describe our 30ml Tincture
Oil that contains 3000 MG CBD Oil and 0% of THC!”
CBD was framed as a natural health product through
descriptions of natural benefits, cultivation methods, or
ingredients. The natural characteristics of CBD were
used by sellers to illustrate its claimed advantages over
conventional products and terminology associated with
natural products emphasized for safety.
Frame #3: a product used in specific ways to achieve
particular results
The third frame, a product used in specific ways to
achieve particular results (n = 1388), utilized characteris-
tics of treatments to describe CBD products and adver-
tise them to potential buyers. These included describing
CBD products in terms of treatment unit quantities, la-
belling the use of CBD products as treatment, offering
comparison to medical or pharmaceutical standards, and
identifying treatment methods of administration. CBD
quantities were characterized as “doses” and contained
language using precise amounts to describe CBD con-
centration. These statements were similar to pharma-
ceutical advice and direction. For example, a CBD
gummy product from happybears.ca stated that “[e] ach
chewy gummy combines a concentrated dose of pure
CBD with the natural calming properties of Melatonin
to promote restful sleep and morning wakefulness.”
Product descriptions contained language that referenced
the person taking CBD as receiving “treatment” or being
a “patient” for using a CBD product. For example, a
zenabis.com CBD spray stated the intended user of their
product was a patient: “Each 0.1 ml spray (at full com-
pression) of Zenabis’ High CBD 30:0 Spray offers pa-
tients 3 mg of CBD and 0 mg of THC in Medium-chain
Triglyceride (MCT) oil.”
Comparisons to existing standards of conventional
treatment were observed in these campaigns. Products
utilized such terminology such as “pharmaceutical
grade” or “medical grade” to support the potential health
impact of product use. For example, a CBD product
from CBD-EEZ on the birachandfog.com website that is
sold in powder form stated: “each effervescent packet
comes with 50mg of 99.9% pharmaceutical grade CBD
to give you easy relief from anxiety, pain, insomnia and/
or stress.” Similarly, the recommended intake method of
CBD emulated conventional treatments. CBD product
administration methods included ingestion, sublingual
intake, topically, through capsules, pills, soft gels, syrin-
ges, suppositories and droppers. For example, an Emer-
ald Health product on the Ontario Cannabis Store
website (ocs.ca) stated: “This flavourless concentrated
cannabis oil comes in a 20-mL bottle which includes a
precision 1mL dosage syringe.” Sellers framed CBD as a
product used in specific ways to achieve particular results
by equating CBD to conventional forms of medications
and treatment.
Discussion
In Canada, the Cannabis Act restricts CBD sellers from
making any suggestion or claim of efficacy for medical
conditions without Health Canada authorization [15,
19]. Nonetheless, the majority of CBD products collected
in our sample (53.3%) made at least one health claim,
confirming the speculation of widespread CBD efficacy
claims in contravention of the Cannabis Act [27, 28].
The top claims – that CBD treats or manages pain (n =
824), anxiety (n = 609), and inflammation (n = 545) –
have been reported on significantly in the media [11, 29,
30]. The range of health uses recorded specifically in-
cluded relief for minor symptoms such as stress (n =
386), disordered sleep (n = 316), muscle relief (n = 236),
and nausea (n = 170). Purported health uses also covered
treatment or symptom relief for chronic or life-
threatening illnesses such as multiple sclerosis (n = 210),
arthritis (n = 179), cancer (n = 169), Parkinson’s disease
(n = 59), and Alzheimer’s diseases (n = 50). Taken to-
gether, these claims demonstrated the multiple uses for
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which CBD products were advertised and sold to Canad-
ian buyers.
Product descriptions commonly framed CBD as a le-
gitimate medicinal product with unique benefits. Sellers
represented CBD as a cure or treatment for specific ail-
ments and equated efficacy in the same terms as
pharmaceutical products, in some cases advocating for
the replacement of conventional products (for example,
for pain relief). Misinterpretation of CBD research and
overvaluation of efficacy testimonials lent credence to
the seller’s assertions that such classification is correct
and appropriate. Specific cure or treatment claims were
supplemented by language for administering CBD prod-
ucts in specific ways to achieve particular results. This
included information and instructions on methods of ad-
ministration (oils/tincture droppers, capsules, syringes,
and suppositories), product measurements and quan-
tities (doses), and treatment protocols. Such instructions
may have been used to reassure users of the product’s
safety and effectiveness. Legitimacy was further estab-
lished through stressing CBD’s natural benefits. These
natural characteristics served to represent CBD as safer
and more effective compared to pharmaceutical
products.
Sellers referenced clinical studies and other sources of
evidence to support the claims made in product descrip-
tions, but the inaccuracies suggested overvaluation of
and confusion regarding extant evidence of CBD’s effi-
cacy as a medical treatment. The majority of sellers ac-
knowledged the limited evidence available regarding
CBD but framed it as a symptom of a new product with
potential medical uses. Through this representation,
sellers then presented the current evidence base as suffi-
cient to demonstrate the plausibility of CBD for specific
uses. Unsupported claims pose a concern for those using
CBD for medical purposes, who may accept the accuracy
of such claims and spend significant amounts of money
on these products for potentially little benefit [31–33].
This is especially concerning in situations when CBD is
purchased to improve or treat life-threatening illnesses
among patients who may forego evidence-based treat-
ments [34–36]. The spread of unproven and, in many
cases, false claims, contributes to the spread of
misinformation.
In response to the findings of the study, it is recom-
mended that Health Canada conduct a systematic in-
spection of cannabis retailers selling CBD products for
adherence to the Cannabis Act. The widespread CBD
claims made by online retailers based in Canada or sell-
ing specifically to Canadian consumers make clear that
non-compliance with existing regulations is prevalent,
thus demonstrating a need to inspect CBD products to
minimize consumer harm. Current risks to consumers
buying CBD products under this context include
unnecessary financial expenditure, purchasing based on
false or unproven claims, and the spread of misinforma-
tion [34, 37, 38]. The authority available to Health
Canada to ensure compliance under the Cannabis Act
includes inspections [39]. Therefore, this is an appropri-
ate intervention. Health Canada has the ability to issue
cautions against those found not to be in compliance, in-
cluding CBD retailers. These cautions can come in the
form of warnings, fines, and additional inspections.
Further research on CBD in the Canadian context is
needed. First, there is a need to investigate adherence to
other Cannabis Act regulations, specifically, plain pack-
aging and non-marketing of cannabis products to chil-
dren. Many products included in the sample did not
adhere to plain packaging restrictions. Labelling con-
cerns are noted in the United States [40]. Products that
appear to appeal to children, such as those mimicking
popular candy bars or child-like characters, were identi-
fied and require further attention. Second, the role of in-
person retail sellers requires analysis. The present study
was limited to online products and thus cannot capture
how retail employees or salespersons frame CBD to pro-
spective consumers and how this may impact their
decision-making.
The study has several limitations. First, the search
strategy likely did not identify every website selling CBD
online in Canada. We lessened this by using multiple ap-
proaches, and the intent of the study was not to identify
every single website selling CBD. Second, a single inves-
tigator reviewed the content and assigned it to the rele-
vant frame, this limitation was mitigated by using a
triangulated approach to troubleshooting.
Conclusion
Online Canadian retailers of CBD typically present prod-
ucts to potential customers through three distinct
frames: a treatment or cure for specific ailments, a nat-
ural health product, and a product used in specific ways
to achieve specific results. The framing of CBD lends
support to the seller’s perception of CBD as a legitimate
option for health purposes, despite a limited, and often
misrepresented, evidence base. Online sellers of CBD in
Canada demonstrate that many CBD products are not
compliant with the Cannabis Act – with the majority of
products in our sample making at least one health claim.
Unproven claims have concerning implications for per-
sons experiencing a medical illness or displaying symp-
toms, through unnecessary financial expenditure and the
ineffectiveness of the product bought. The frames identi-
fied also contribute to the spread of CBD misinforma-
tion. Regulatory action is needed to monitor and inspect
CBD sellers and ensure they comply with the Cannabis
Act.
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